Skip to main content
Top
Published in: Reactions Weekly 1/2022

01-05-2022 | Glioma | Case report

Bevacizumab/irinotecan

Deep vein thrombosis: case report

Published in: Reactions Weekly | Issue 1/2022

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference de Marcellus C, et al. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. Journal of Neuro-Oncology 157: 355-364, No. 2, Apr 2022. Available from: URL: http://doi.org/10.1007/s11060-022-03970-4 de Marcellus C, et al. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. Journal of Neuro-Oncology 157: 355-364, No. 2, Apr 2022. Available from: URL: http://​doi.​org/​10.​1007/​s11060-022-03970-4
Metadata
Title
Bevacizumab/irinotecan
Deep vein thrombosis: case report
Publication date
01-05-2022
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15848-4

Other articles of this Issue 1/2022

Reactions Weekly 1/2022 Go to the issue

Case report

AZD-1222

Case report

Nivolumab

Case report

Doxorubicin

Case report

Prednisone